Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report details a specific share repurchase transaction executed on August 6, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 400,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,509.5 pence per share; lowest price paid was 1,487 pence per share.
- Treasury Holdings (Settled): 484,607,927 shares (8.86% of total issued share capital).
- Treasury Holdings (Including Unsettled): 486,507,927 shares (9.76% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,985,737,903 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 400,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior settled position to 9.76% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (484,607,927 settled) against the company's latest capitalization table.
- Confirm the total voting rights denominator (4,985,737,903 shares) for disclosure threshold calculations.
- Check the average price paid for the 400,000 shares against the market price on August 6, 2012.
- Review the remaining authorization for share buybacks under the May 3, 2012 shareholder mandate.